Sino Biopharmaceutical (Sino Biopharmaceutical) Other Long Term Assets : $3,778 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Other Long Term Assets?

Sino Biopharmaceutical's other long-term assets for the quarter that ended in Dec. 2023 was $3,778 Mil.

Sino Biopharmaceutical's quarterly other long-term assets declined from Dec. 2022 ($3,868 Mil) to Jun. 2023 ($3,650 Mil) but then increased from Jun. 2023 ($3,650 Mil) to Dec. 2023 ($3,778 Mil).

Sino Biopharmaceutical's annual other long-term assets declined from Dec. 2021 ($4,210 Mil) to Dec. 2022 ($3,868 Mil) and declined from Dec. 2022 ($3,868 Mil) to Dec. 2023 ($3,778 Mil).

Sino Biopharmaceutical Other Long Term Assets Historical Data

The historical data trend for Sino Biopharmaceutical's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Other Long Term Assets Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

506.83

2,295.41

4,209.59

3,867.60

3,778.35

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long Term Assets	Get a 7-Day Free Trial															4,209.59	4,347.53	3,867.60	3,649.80	3,778.35

Sino Biopharmaceutical Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.